Montag, 29. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
PANTAX-Ib

Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

Rekrutierend

NCT-Nummer:
NCT04652206

Studienbeginn:
Oktober 2020

Letztes Update:
29.12.2021

Wirkstoff:
SCO-101, Gemcitabine, nab paclitaxel

Indikation (Clinical Trials):
Adenocarcinoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Scandion Oncology A/S

Collaborator:
Alcedis GmbH

Kontakt

Studienlocations
(3 von 4)

Alle anzeigen

Studien-Informationen

Detailed Description:

The study is an open-label dose escalating phase Ib study of SCO-101 in combination with

gemcitabine and nab-paclitaxel. The primary objective is to establish the safety,

tolerability and MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. Secondary

objectives are efficacy and to establish PK parameters of SCO-101. The target indication is

patients with inoperal pancreatic cancer who are to be treated with gemcitabine and

nab-paclitaxel. The study is designed as a standard 3+3 dose escalation study with increasing

doses of SCO-101 and a fixed dose (standard regimen) of gemcitabine and nab-paclitaxel. An

interim report will be prepared once the last patient in the MTD cohort has completed one

treatment cycle. Patients will continue treatment until disease progression to evaluate

secondary objectives. One treatment Cycle is 28 days. The starting dose of SCO-101 is 150 mg

6 daily dosing in a bi-weekly schedule) and may be increased to a maximum of 350 mg (5

cohorts with 50 mg increments). A total of up to 18 patients are anticipated if dose

escalation to the 5th cohort. Gemcitabine and nab-paclitaxel is administered according to

local standard recommendations once weekly for three weeks followed by one weeks treatment

holiday (dosing on day 6, day 13 and day 20). Patients may continue treatment until treatment

progression.

Ein-/Ausschlusskriterien

Inclusion Criteria:

Patients are required to meet all of the following criteria for enrollment into the study:

1. Ability to understand and willingness to provide written informed consent before any

trial-related activities.

2. Age 18 years or older.

3. Histologically or cytologically verified pancreatic adenocarcinoma.

4. Inoperable localized, locally advanced or metastatic pancreatic cancer, not amenable

for curatively intended treatment, in patients who are to be treated with gemcitabine

and nab-paclitaxel.

5. Measurable or non-measurable disease determined by CT scan or MRI, according to RECIST

1.1.

6. Performance status of ECOG ≤ 2 and expected to tolerate the standard recommended

(100%) gemcitabine and nab-paclitaxel dose.

7. Recovered to Grade 1 or less from prior surgery or acute toxicities of prior

radiotherapy or treatment with cytotoxic or biologic agents.

8. ≥ 2 weeks must have elapsed since any prior surgery or radiotherapy.

9. Adequate conditions as evidenced by the following clinical laboratory values:

- Absolute neutrophils count (ANC) ≥ 1.5 x 109/L

- Haemoglobin ≥ 6.0 mmol/L

- Platelets ≥ 100 x 109 /L

- Alanine aminotransferase (ALT) ≤ 2.5 x ULN and aspartate aminotransferase (AST) ≤

2.5 x ULN*

- Total Serum bilirubin ≤ 1.0 ULN

- Alkaline phosphatase ≤ 2.5 x ULN*

- Creatinine ≤ 1.5 ULN

- eGFR within normal limits

- Adequate blood clothing function as defined by the International Normalized Ratio

(INR) ≤ 1.2

10. Life expectancy longer than 3 months.

11. Sexually active males and females of child-producing potential must use highly

effective contraception (intrauterine devices, hormonal contraceptives (contraceptive

pills, implants, transdermal patches, hormonal vaginal devices or injections with

prolonged release)) for the study duration and at least 6 months after the last dose

of study drug.

12. Signed informed consent. *AST is not mandatory. In case of known liver metastases with

ALT and AST ≤ 5 x ULN and/or alkaline phosphatase ≤ 5 x ULN: Patients who do not

conform to the transaminase and/or alkaline phosphatase inclusion criteria, but who by

the PI are considered in good PS and otherwise eligible for inclusion, and where the

transaminase and/or alkaline phosphatase levels are considered elevated due to other

reasons than deteriorated lever capacity, may be considered for inclusion based on

conferred agreement between PI and sponsor.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from enrollment:

1. Concurrent chemotherapy, radiotherapy, or other investigational drug during study

period.

2. Previous surgeries with resection of the complete stomach or greater part of small

intestines (excluding the duodenum), whereby absorption of SCO-101 may be affected.

Treatment with Creon or similar is allowed.

3. Difficulty in swallowing tablets.

4. CNS metastases requiring steroids.

5. Treatment with antibiotics for infections or with clinical symptoms of active

infection. Patients showing symptoms of CoViD19 must be tested for active CoViD19

infection.

6. Known HIV positivity.

7. Known active hepatitis B or C.

8. Clinically significant (i.e. active) cardiovascular disease:

- Stroke, Transient ischemic attack (TIA) or myocardial infarction within ≤ 6

months prior to day 1.

- Unstable angina or NYHA Grade II or greater congestive heart failure (CHF).

- Serious cardiac arrhythmia requiring medication.

9. Mental status, symptomatic epilepsy or other CNS disease where the investigator

assesses the patient not fit for the clinical study.

10. Other medications or conditions that in the Investigator's opinion would

contraindicate study participation of safety reasons or interfere with the

interpretation of study results. Other severe medical conditions, including serious

heart disease, unstable diabetes, uncontrolled hypercalcemia or previous organ

transplants. Participation in another clinical trial with experimental medication

within 30 days prior to registration.

11. Known hypersensitivity to gemcitabine and/or nab-paclitaxel.

12. Pregnant women or women who are breastfeeding.

13. Prior or present neuropathy > grade I (NCI-CTCAE v.5.0).

14. Curatively intended treatment.

Studien-Rationale

Primary outcome:

1. Safety and Tolerability (Time Frame - Through study completion, assessed up to 100 months):
Safety and tolerability by assessing the number, frequency, and severity of adverse events (AEs) collected from the time of first treatment until four weeks after end of treatment to evaluate safety of SCO-101 in combination with gemcitabine and nab-paclitaxel determined according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE v.5.0).

2. Maximum Tolerated Dose (Time Frame - At the end of Cycle 1 (each cycle is 28 days)):
To determine the Maximum Tolerated Dose (MTD) of SCO-101 in combination with gemcitabine and nab-Paclitaxel by assessment of Dose Limiting Toxicities (DLT) to SCO-101.

Secondary outcome:

1. Objective Response Rate (Time Frame - Tumor assessment is performed every two treatment cycles (2 months), assessed up to 100 months.):
defined as CR and PR using the RECIST v. 1.1

2. Clinical Benefit Rate (CBR) (Time Frame - From benefit (CR, PR or SD > 16 weeks) to progression, assessed up to 100 months):
defined as the number of patients obtaining CR, PR, or SD > 16 weeks according to RECIST v.1.1.

3. Progression Free Survival (PFS) (Time Frame - From first dosing to progression, assessed up to 100 months):
defined as time in months from the date of first study treatment with SCO-101 to the date of disease progression or death from any cause, whichever comes first.

4. Overall Survival (Time Frame - through study completion, assessed up to 100 months):
defined as time in months from the date of first study treatment to the date of death

5. Pharmacokinetic profile (Time Frame - during the first 14 treatment days in the first treatment cycle.):
Pharmacokinetic profile of SCO-101 alone and in combination with gemcitabine and nab-paclitaxel

Geprüfte Regime

  • SCO-101:
    Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
  • Gemcitabine:
    Used according to marketing authorisation
  • Nab paclitaxel:
    Used according to marketing authorisation

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients."

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.